WHY:
New York, NY – 
(NewMediaWire) – January 19, 2022 – Rosen
Law Firm, a global investor rights law firm, reminds purchasers of the
securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November
25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important
February 8, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Revance securities during
the Class Period you may be entitled to compensation without payment of any out
of pocket fees or costs through a contingency fee arrangement.
WHAT TO
DO NEXT: To join
the Revance
class action, go
to http://www.rosenlegal.com/cases-register-2179.html
or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on
the class action. A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than February 8,
2022. A lead plaintiff is a representative party acting on behalf of other
class members in directing the litigation.
WHY
ROSEN LAW: We encourage investors to
select qualified counsel with a track record of success in leadership roles.
Often, firms issuing notices do not have comparable experience, resources or
any meaningful peer recognition. Many of these firms do not actually litigate
securities class actions. Be wise
in selecting counsel. The Rosen Law Firm represents investors throughout the
globe, concentrating its practice in securities class actions and shareholder
derivative litigation. Rosen Law Firm has achieved the largest ever securities
class action settlement against a Chinese Company. Rosen Law Firm was Ranked
No. 1 by ISS Securities Class Action Services for number of securities class
action settlements in 2017. The firm has been ranked in the top 4 each year
since 2013 and has recovered hundreds of millions of dollars for investors. In
2019 alone the firm secured over $438 million for investors. In 2020, founding
partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many
of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS
OF THE CASE: According to the
lawsuit, defendants throughout the Class Period made false and/or misleading
statements and/or failed to disclose that: (1) quality control deficiencies
existed at Revance’s manufacturing facility for DaxibotulinumtoxinA
for injection (“DAXI”), the Company’s lead drug candidate; (2) the foregoing deficiencies decreased the
likelihood that the U.S. Food and Drug Administration (“FDA”)
would approve the DAXI Biologics
License Application (“BLA”) in its
current form; (3) accordingly, it was unlikely that the DAXI BLA would obtain
FDA approval within the timeframe Revance had represented to
investors; and (4) as a result, defendants’ public statements were materially
false and misleading at all relevant times. When the true details entered the
market, the lawsuit claims that investors suffered damages.
To join the Revance class action, go to http://www.rosenlegal.com/cases-register-2179.html
or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on
the class action.
No Class Has Been
Certified. Until a class is certified, you are not represented by counsel
unless you retain one. You may select counsel of your choice. You may also remain
an absent class member and do nothing at this point. An investor’s ability to
share in any potential future recovery is not dependent upon serving as lead
plaintiff.
Follow us for updates on
LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm,
on Twitter: https://twitter.com/rosen_firm
or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior
results do not guarantee a similar outcome.
——————————-
Contact
Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View the original release on www.newmediawire.com